94 related articles for article (PubMed ID: 25931259)
1. Neoplastic spindle cells are an independent prognostic factor in pancreatic cancer.
Takahashi K; Hisaka T; Horiuchi H; Ishikawa H; Nakayama M; Nakashima O; Kawahara A; Kage M; Yano H; Akagi Y; Yonemoto K; Kinoshita H; Shirouzu K
Pancreas; 2015 Jul; 44(5):742-9. PubMed ID: 25931259
[TBL] [Abstract][Full Text] [Related]
2. Epithelial-to-mesenchymal transition (EMT) in intraductal papillary mucinous neoplasm (IPMN) is associated with high tumor grade and adverse outcomes.
Lahat G; Lubezky N; Loewenstein S; Nizri E; Gan S; Pasmanik-Chor M; Hayman L; Barazowsky E; Ben-Haim M; Klausner JM
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S750-7. PubMed ID: 25069861
[TBL] [Abstract][Full Text] [Related]
3. CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival.
Lee SH; Kim H; Hwang JH; Shin E; Lee HS; Hwang DW; Cho JY; Yoon YS; Han HS; Cha BH
Pancreas; 2014 Apr; 43(3):380-8. PubMed ID: 24622067
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of homeobox B-13 correlates with angiogenesis, aberrant expression of EMT markers, aggressive characteristics and poor prognosis in pancreatic carcinoma.
Zhai LL; Wu Y; Cai CY; Tang ZG
Int J Clin Exp Pathol; 2015; 8(6):6919-27. PubMed ID: 26261579
[TBL] [Abstract][Full Text] [Related]
5. Mortalin expression in pancreatic cancer and its clinical and prognostic significance.
Cui X; Li Z; Piao J; Li J; Li L; Lin Z; Jin A
Hum Pathol; 2017 Jun; 64():171-178. PubMed ID: 28412209
[TBL] [Abstract][Full Text] [Related]
6. Epithelial-mesenchymal transition markers in pancreatic ductal adenocarcinoma.
Cates JM; Byrd RH; Fohn LE; Tatsas AD; Washington MK; Black CC
Pancreas; 2009 Jan; 38(1):e1-6. PubMed ID: 18766116
[TBL] [Abstract][Full Text] [Related]
7. Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients.
Guo S; Jing W; Hu X; Zhou X; Liu L; Zhu M; Yin F; Chen R; Zhao J; Guo Y
Int J Cancer; 2014 Mar; 134(6):1369-78. PubMed ID: 24037692
[TBL] [Abstract][Full Text] [Related]
8. Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma.
O'Connor K; Li-Chang HH; Kalloger SE; Peixoto RD; Webber DL; Owen DA; Driman DK; Kirsch R; Serra S; Scudamore CH; Renouf DJ; Schaeffer DF
Am J Surg Pathol; 2015 Apr; 39(4):472-8. PubMed ID: 25634751
[TBL] [Abstract][Full Text] [Related]
9. Detailed analysis of epithelial-mesenchymal transition and tumor budding identifies predictors of long-term survival in pancreatic ductal adenocarcinoma.
Kohler I; Bronsert P; Timme S; Werner M; Brabletz T; Hopt UT; Schilling O; Bausch D; Keck T; Wellner UF
J Gastroenterol Hepatol; 2015 Mar; 30 Suppl 1():78-84. PubMed ID: 25827809
[TBL] [Abstract][Full Text] [Related]
10. Expression of SNAIL in accompanying PanIN is a key prognostic indicator in pancreatic ductal adenocarcinomas.
Fujiwara S; Saiki Y; Ishizawa K; Fukushige S; Yamanaka M; Sato M; Ishida M; Motoi F; Unno M; Horii A
Cancer Med; 2019 Apr; 8(4):1671-1678. PubMed ID: 30791220
[TBL] [Abstract][Full Text] [Related]
11. Mucin expression in endoscopic ultrasound-guided fine-needle aspiration specimens is a useful prognostic factor in pancreatic ductal adenocarcinoma.
Higashi M; Yokoyama S; Yamamoto T; Goto Y; Kitazono I; Hiraki T; Taguchi H; Hashimoto S; Fukukura Y; Koriyama C; Mataki Y; Maemura K; Shinchi H; Jain M; Batra SK; Yonezawa S
Pancreas; 2015 Jul; 44(5):728-34. PubMed ID: 25906442
[TBL] [Abstract][Full Text] [Related]
12. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
[TBL] [Abstract][Full Text] [Related]
13. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
Meng FD; Wei JC; Qu K; Wang ZX; Wu QF; Tai MH; Liu HC; Zhang RY; Liu C
World J Gastroenterol; 2015 Jan; 21(1):196-213. PubMed ID: 25574092
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Prognostic Significance of Neoplastic Spindle Cells in Gallbladder Cancer.
Midorikawa R; Hisaka T; Sakai H; Nomura Y; Goto Y; Sato T; Kawahara R; Ishikawa H; Fujita F; Yasunaga M; Tanigawa M; Naito Y; Akiba J; Yano H; Tanaka H; Akagi Y; Okuda K
Anticancer Res; 2019 Aug; 39(8):4561-4568. PubMed ID: 31366560
[TBL] [Abstract][Full Text] [Related]
15. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
[TBL] [Abstract][Full Text] [Related]
16. Paraneoplastic Ma Antigen-Like 1 as a Potential Prognostic Biomarker in Human Pancreatic Ductal Adenocarcinoma.
Kuwae Y; Kakehashi A; Wakasa K; Wei M; Yamano S; Ishii N; Ohsawa M; Wanibuchi H
Pancreas; 2015 Jan; 44(1):106-15. PubMed ID: 25251443
[TBL] [Abstract][Full Text] [Related]
17. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
[TBL] [Abstract][Full Text] [Related]
18. Histopathological tumor invasion of the mesenterico-portal vein is characterized by aggressive biology and stromal fibroblast activation.
Lapshyn H; Bolm L; Kohler I; Werner M; Billmann FG; Bausch D; Hopt UT; Makowiec F; Wittel UA; Keck T; Bronsert P; Wellner UF
HPB (Oxford); 2017 Jan; 19(1):67-74. PubMed ID: 27825542
[TBL] [Abstract][Full Text] [Related]
19. B7-H4 is a prognostic biomarker for poor survival in patients with pancreatic cancer.
Shen L; Qian Y; Wu W; Weng T; Wang FXC; Hong B; Wu Z; Wang Q; Sang Y; Zhang H; Zhou X; Yao H
Hum Pathol; 2017 Aug; 66():79-85. PubMed ID: 28600225
[TBL] [Abstract][Full Text] [Related]
20. Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival.
Nordby T; Hugenschmidt H; Fagerland MW; Ikdahl T; Buanes T; Labori KJ
Eur J Surg Oncol; 2013 Jun; 39(6):559-66. PubMed ID: 23498362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
